Literature DB >> 11443619

beta-Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance.

C M Wong1, S T Fan, I O Ng.   

Abstract

BACKGROUND: beta-Catenin has been recognized as a critical member of the Wnt signaling pathway, and inappropriate activation of this pathway has been implicated in carcinogenesis.
METHODS: To determine the clinical significance of beta-catenin in hepatocellular carcinoma (HCC), we performed mutational analysis at exon 3 of the gene, investigated the subcellular protein expression, and analyzed their clinicopathologic and prognostic significance in 60 patients with resected primary HCC.
RESULTS: By direct DNA sequencing, somatic mutations of the beta-catenin gene were detected in 7 (12%) HCCs. All the mutations were found at the region (exon 3) responsible for phosphorylation and ubiquitination, therefore likely to result in stabilization of free cytoplasmic beta-catenin. Nuclear accumulation of the beta-catenin protein, similar to the response to the Wnt signal, was found in 10 (17%) HCCs and was closely associated with gene mutation (P < 0.001). In the remaining cases, nonnuclear type overexpression, that is, overexpression in the cytoplasm and/or cytoplasmic membrane, was observed in 31 (62%) HCCs, thus suggesting that the mechanisms leading to beta-catenin overexpression may be heterogeneous. HCCs with a nonnuclear type of beta-catenin overexpression were more frequently larger than 5 cm in diameter (P = 0.022) and had poorer cellular differentiation (P = 0.037), and the patients had significantly shorter disease-free survival lengths (P = 0.041). Review of the data from previous studies in HCC showed that beta-catenin mutations were more frequent in HCV-associated HCC than in HBV-associated ones.
CONCLUSIONS: beta-catenin mutation and deregulation may play an important role in hepatocarcinogenesis. Nonnuclear type beta-catenin overexpression appeared to have pathologic and prognostic significance. Copyright 2001 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11443619     DOI: 10.1002/1097-0142(20010701)92:1<136::aid-cncr1301>3.0.co;2-r

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  116 in total

1.  Conditional beta-catenin loss in mice promotes chemical hepatocarcinogenesis: role of oxidative stress and platelet-derived growth factor receptor alpha/phosphoinositide 3-kinase signaling.

Authors:  Xu-Feng Zhang; Xinping Tan; Gang Zeng; Amalea Misse; Sucha Singh; Youngsoo Kim; James E Klaunig; Satdarshan P S Monga
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

2.  Expression and Prognostic Significance of CDK8 and β-Catenin in Hepatocellular Carcinoma.

Authors:  Song Iy Han; Sung-Chul Lim
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

Review 3.  Beta-catenin signaling, liver regeneration and hepatocellular cancer: sorting the good from the bad.

Authors:  Kari Nichole Nejak-Bowen; Satdarshan P S Monga
Journal:  Semin Cancer Biol       Date:  2010-12-21       Impact factor: 15.707

Review 4.  Genetics of hepatocellular carcinoma.

Authors:  Andreas Teufel; Frank Staib; Stephan Kanzler; Arndt Weinmann; Henning Schulze-Bergkamen; Peter-R Galle
Journal:  World J Gastroenterol       Date:  2007-04-28       Impact factor: 5.742

5.  Wnt/beta-catenin signaling in hepatic organogenesis.

Authors:  Kari Nejak-Bowen; Satdarshan Ps Monga
Journal:  Organogenesis       Date:  2008-04       Impact factor: 2.500

Review 6.  Hepatocelluar carcinoma associated with attenuated familial adenomatous polyposis: a case report and review of the literature.

Authors:  Mingqing Li; David A Gerber; Mark Koruda; Bert H O'Neil
Journal:  Clin Colorectal Cancer       Date:  2011-08-02       Impact factor: 4.481

Review 7.  Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy.

Authors:  Renumathy Dhanasekaran; Jean-Charles Nault; Lewis R Roberts; Jessica Zucman-Rossi
Journal:  Gastroenterology       Date:  2018-11-04       Impact factor: 22.682

Review 8.  Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?

Authors:  Kiruthikah Thillai; Paul Ross; Debashis Sarker
Journal:  World J Gastrointest Oncol       Date:  2016-02-15

Review 9.  Wnt signaling in liver cancer.

Authors:  Yutaka Takigawa; Anthony M C Brown
Journal:  Curr Drug Targets       Date:  2008-11       Impact factor: 3.465

Review 10.  DNA markers in molecular diagnostics for hepatocellular carcinoma.

Authors:  Ying-Hsiu Su; Selena Y Lin; Wei Song; Surbhi Jain
Journal:  Expert Rev Mol Diagn       Date:  2014-08-07       Impact factor: 5.225

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.